The results of human xenograft tumor models indicated that FRRG-DOX could improve targeting efficiency and antitumor efficacy against Cat-B-overexpressed cancer cells, and it did not cause severe toxicity in normal tissues owing to the low expression of Cat-B. The gene discussed is TYRP1; the disease is neoplasm.